POA is a Phase III parallel‑group, open‑label, multi‑country, multi‑centre randomised controlled trial evaluating a new once‑weekly oral long‑acting antiretroviral regimen to determine whether it maintains viral suppression as effectively as daily therapy. The trial is coordinated by the University of St Andrews, with support from the University of Liverpool and Università degli Studi di Torino, and is being conducted in Uganda, Kenya, Côte d’Ivoire, and Zimbabwe to compare this regimen with standard first‑line treatment in adults who are already virologically suppressed. Feasibility, safety, and cost‑effectiveness will also be assessed to inform potential integration of this regimen into routine HIV care.
Clinical Trials
